ALLMedicine™ Astrocytoma Center
Research & Reviews 1,707 results
https://clinicaltrials.gov/ct2/show/NCT02644291
Jun 23rd, 2022 - The primary objectives of this study are to determine the maximum tolerated dose (MTD) of oral mebendazole in patients with recurrent/progressive pediatric brain tumors and to confirm the tolerance of the MTD of oral mebendazole by assessing toler...
https://doi.org/10.1007/s00401-022-02447-y 10.3988/jcn.2019.15.1.125 10.1007/s00415-018-8970-0 10.4161/cbt.9.6.10898 10.1186/s40478-019-0693-7 10.1007/s00401-019-02081-1 10.1016/s1474-4422(08)70224-2 10.1001/jamaneurol.2014.488 10.1523/jneurosci.0167-10.2010 10.1186/s12883-019-1436-x 10.1093/neuonc/nov297 10.1002/ana.23689 10.1186/s40478-020-00902-z 10.1007/s00381-020-04900-3 10.1016/s1474-4422(12)70310-1 10.1007/s00401-019-02078-w
Acta Neuropathologica; Nikolaus M, Koch A et. al.
Jun 22nd, 2022 - Atypical NMDA receptor expression in a diffuse astrocytoma, MYB- or MYBL1-altered as a trigger for autoimmune encephalitis.|2022|Nikolaus M,Koch A,Stenzel W,Elezkurtaj S,Sahm F,|
https://doi.org/10.1186/s40478-022-01392-x 10.1002/1097-0142(19841201)54:11<2505::AID-CNCR2820541132>3.0.CO;2-G 10.1016/0303-8467(94)00051-7 10.1007/PL00007280 10.1007/s00381-003-0888-9 10.1016/j.neurad.2008.04.003 10.1007/s11060-009-0075-2 10.1007/s10014-014-0179-z 10.1158/1541-7786.MCR-17-0507 10.1016/j.humpath.2018.06.005 10.1016/j.jocn.2006.01.024 10.1007/s00381-011-1587-6 10.5414/NP300548 10.1097/NEN.0b013e3182a033a0 10.1111/nan.12072 10.1007/s00381-015-2715-5 10.1002/pbc.26350 10.3171/2018.4.PEDS17638 10.1002/pbc.26893 10.1158/2159-8290.CD-19-1030 10.1007/s00381-021-05057-3 10.1111/nan.12801 10.1111/j.1750-3639.1993.tb00754.x 10.1159/000120701 10.1080/02688699650040412 10.1016/S0046-8177(96)90171-9 10.1023/A:1016309813752 10.3171/PED/2008/1/2/148 10.1177/0883073809333542 10.5414/NP300945 10.1007/s00401-011-0802-6 10.1038/s41467-019-12187-5 10.1111/j.1349-7006.2009.01308.x 10.1038/ng.556 10.1158/0008-5472.CAN-10-2488 10.1093/jnci/91.22.1922 10.1158/0008-5472.CAN-07-6867 10.1016/j.neuroscience.2015.04.005 10.3171/2010.8.JNS1081
Acta Neuropathologica Communications; Megías J, San-Miguel T et. al.
Jun 21st, 2022 - Desmoplastic infantile astrocytoma (DIA) is rare, cystic and solid tumor of infants usually found in superficial cerebral hemispheres. Although DIA is usually benign, uncommon cases bearing malignant histological and aggressive clinical features h...
https://doi.org/10.1016/j.wneu.2022.06.045
World Neurosurgery; McDonald MF, Rao G et. al.
Jun 20th, 2022 - A 25-year-old male presented with headaches 3 weeks after a car accident. His MRI images showed a hemorrhagic vermis mass with 4th ventricle effacement. One month later, he underwent suboccipital craniotomy for removal of a pilocytic astrocytoma. ...
https://doi.org/10.1016/j.tcam.2022.100681
Topics in Companion Animal Medicine; Schwab ML, Ferrarin DA et. al.
Jun 20th, 2022 - Bichon Frise (1) and Boxer (2), both with epileptic seizures, underwent lumbar taps for cerebrospinal fluid collection. After the examination, the first dog became paraplegic, and the second dog did not recover from anesthesia and remained in a co...
Guidelines 3 results
https://doi.org/10.1200/JCO.21.02036
Journal of Clinical Oncology : Official Journal of the Am... Mohile NA, Messersmith H et. al.
Dec 14th, 2021 - To provide guidance to clinicians regarding therapy for diffuse astrocytic and oligodendroglial tumors in adults. ASCO and the Society for Neuro-Oncology convened an Expert Panel and conducted a systematic review of the literature. Fifty-nine rand...
https://doi.org/10.1007/s11060-015-1931-x
Journal of Neuro-oncology; Ziu M, Kalkanis SN et. al.
Nov 5th, 2015 - Adult patients (older than 18 years of age) with newly diagnosed World Health Organization (WHO) Grade II gliomas (Oligodendroglioma, astrocytoma, mixed oligoastrocytoma). Is there a role for chemotherapy as adjuvant therapy of choice in treatment...
https://doi.org/10.1007/s11060-015-1867-1
Journal of Neuro-oncology; Aghi MK, Nahed BV et. al.
Nov 5th, 2015 - Should patients with imaging suggestive of low grade glioma (LGG) undergo observation versus treatment involving a surgical procedure? These recommendations apply to adults with imaging suggestive of a WHO grade 2 glioma (oligodendroglioma, astroc...
Drugs 33 results see all →
Clinicaltrials.gov 139 results
https://clinicaltrials.gov/ct2/show/NCT02644291
Jun 23rd, 2022 - The primary objectives of this study are to determine the maximum tolerated dose (MTD) of oral mebendazole in patients with recurrent/progressive pediatric brain tumors and to confirm the tolerance of the MTD of oral mebendazole by assessing toler...
https://clinicaltrials.gov/ct2/show/NCT04047303
Jun 14th, 2022 - CC-90010-GBM-001 is a multi-center, open-label study to assess the pharmacokinetics (PK), pharmacodynamics (PD) and CNS penetration of CC-90010 following short-term interval therapy (4 daily doses ) prior to surgery, in subjects with progressive o...
https://clinicaltrials.gov/ct2/show/NCT01466686
Jun 13th, 2022 - In vitro and in vivo studies have suggested that low dose fractionated radiation therapy (LDFRT) may be used to potentiate full dose chemotherapy, decreasing the development of resistance found with standard doses of radiation and chemotherapy. Th...
https://clinicaltrials.gov/ct2/show/NCT04757662
Jun 10th, 2022 - Increasing preclinical and clinical data have shown that myeloid-derived suppressor cells (MDSCs) may represent a significant driver of immunosuppression in glioblastoma (GBM, grade IV astrocytoma) and a potential mechanism of treatment resistance...
https://clinicaltrials.gov/ct2/show/NCT03528642
Jun 8th, 2022 - PRIMARY OBJECTIVE: I. Determine the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) of telaglenastat (CB-839) hydrochloride (HCl) when combined with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagn...
News 79 results
https://www.onclive.com/view/targeted-combo-notches-rare-success-in-glioblastoma
Mar 30th, 2022 - For more than 20 years, investigators have tried numerous targeted therapy strategies against glioblastoma (GBM) that have fallen frustratingly short in establishing clinical benefit.1 That changed in November 2021 when an international team of in...
https://www.onclive.com/view/net-guides-childhood-tumors
Mar 15th, 2022 - //THE ONLINE ONCOLOGIST™ American Society of Pediatric Hematology/Oncology The American Society of Pediatric Hematology/Oncology (ASPHO) is a multidisciplinary organization that works to promote the care of children and adolescents with blo...
https://www.medscape.com/viewarticle/968594
Feb 15th, 2022 - New research shows that men in their 20s and 30s have worse survival from many different types of brain tumors than women of the same age. And, researchers say, it’s not exactly clear why. Differences in treatment may mediate some of the associati...
https://www.onclive.com/view/exceptional-responder-provides-treatment-clues-in-bladder-cancer
Oct 6th, 2021 - Nikhil Wagle, MD An exceptional responder with advanced urothelial carcinoma experienced a complete radiologic response lasting 13.8 months following treatment with the combination of everolimus (Afinitor) and pazopanib (Votrient), according to r...
https://www.onclive.com/view/selumetinib-response-not-driven-by-mapk-expression-in-pediatric-and-aya-refractory-solid-tumors
Jun 10th, 2021 - Selumetinib did not elicit clinical activity in pediatric and young adult patients with refractory cancers who had actionable mutations in the RAS/RAF/MAPK1/2-ERK pathway, according to cohort findings from the phase 2, single-arm National Cancer I...